Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
20–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Male ≥ 20 years of age
Histologically or cytologically confirmed adenocarcinoma of the prostate
Presents with at least 2 bone metastases, confirmed by scintigraphic imaging within the previous 4 weeks
Patients who has failed initial hormonal therapy using either an orchiectomy or a Gonadotropin releasing hormone (GnRH) agonist in combination with an antiandrogen must first progress through antiandrogen withdrawal prior to being eligible. The minimum timeframe to document failure of anti-androgen withdrawal will be four weeks
Castrate level of testosterone (\<50 ng/dL), treatment to maintain castrate levels of testosterone must be continued
You may not be if
Has received an investigational drug in the 4 weeks before or is scheduled to receiving one during or in the 8 weeks after study drug administration.
Has received chemo-, immuno-, or radiotherapy within the last 4 weeks prior to entry in the study, or has not recovered from acute adverse events as a result of such therapy
Has received prior hemibody external radiotherapy
Has a need for immediate external radiotherapy
Has received systemic radiotherapy with radium-223, strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last 24 weeks prior to administration of study drug
When receiving bisphosphonates, has changed the dose within 4 weeks before administration of study drug
Clareo Health | Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese Patients
